IMMUNITYBIO, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
IMMUNITYBIO, INC. (IBRX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $119.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-04
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $40.30M.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $79.38M, a 1383.78% increase year-over-year.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $59.55M, a 230.19% increase year-over-year.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $64.90M, a 43.85% decline from fiscal 2024.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $115.59M, a 1044.42% increase from fiscal 2023.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $10.10M, a 92.12% decline from fiscal 2022.
- IMMUNITYBIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $128.19M, a 128.23% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $40.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $119.68M 10-Q · filed 2026-08-04 | $179.23M derived: sum of 3 quarters · filed 2026-08-04 | $179.23M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $79.38M 10-Q · filed 2026-05-07 | $138.93M derived: sum of 2 quarters · filed 2026-05-07 | $138.93M derived: sum of 3 quarters · filed 2026-05-07 | $138.93M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $59.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $59.55M derived: sum of 2 quarters · filed 2026-02-23 | $59.55M derived: sum of 3 quarters · filed 2026-08-04 | $64.90M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $5.35M 10-Q · filed 2025-11-05 | $23.38M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.35M 10-Q · filed 2026-08-04 | $23.38M derived: sum of 3 quarters · filed 2026-08-04 | $72.92M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $5.35M 10-Q · filed 2026-05-07 | $23.38M derived: sum of 2 quarters · filed 2026-05-07 | $72.92M derived: sum of 3 quarters · filed 2026-05-07 | $107.92M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $18.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $67.56M derived: sum of 2 quarters · filed 2026-02-23 | $102.56M derived: sum of 3 quarters · filed 2026-02-23 | $115.59M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $49.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $84.53M derived: sum of 2 quarters · filed 2025-11-05 | $97.55M 10-Q · filed 2025-11-05 | $107.65M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $48.02M 10-Q · filed 2025-08-05 | $58.12M derived: sum of 3 quarters · filed 2026-02-23 | $58.12M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $13.02M 10-Q · filed 2025-05-12 | $23.12M derived: sum of 2 quarters · filed 2026-02-23 | $23.12M derived: sum of 3 quarters · filed 2026-02-23 | $23.12M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $10.10M derived: sum of 2 quarters · filed 2026-02-23 | $10.10M derived: sum of 3 quarters · filed 2026-02-23 | $10.10M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $14.75M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $14.75M derived: sum of 3 quarters · filed 2025-03-03 | $113.84M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $14.75M derived: sum of 2 quarters · filed 2025-03-03 | $113.84M derived: sum of 3 quarters · filed 2025-03-03 | $128.19M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $14.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $113.84M derived: sum of 2 quarters · filed 2023-11-09 | $128.19M 10-Q · filed 2023-11-09 | $139.59M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | $99.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $113.43M 10-Q · filed 2023-08-08 | $124.84M derived: sum of 3 quarters · filed 2024-03-19 | $125.44M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $14.35M 10-Q · filed 2023-05-11 | $25.75M derived: sum of 2 quarters · filed 2024-03-19 | $26.35M derived: sum of 3 quarters · filed 2024-03-19 | $38.59M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | $11.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $12.01M derived: sum of 2 quarters · filed 2024-03-19 | $24.24M derived: sum of 3 quarters · filed 2024-03-19 | $56.17M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $12.83M derived: sum of 2 quarters · filed 2022-11-09 | $44.76M 10-Q · filed 2022-11-09 | $103.53M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $12.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $44.16M 10-Q · filed 2022-08-08 | $102.93M derived: sum of 3 quarters · filed 2023-03-01 | $66.59M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $31.93M 10-Q · filed 2022-05-10 | $90.69M derived: sum of 2 quarters · filed 2023-03-01 | $54.35M derived: sum of 3 quarters · filed 2023-03-01 | $74.17M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $58.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $22.43M derived: sum of 2 quarters · filed 2023-03-01 | $42.24M derived: sum of 3 quarters · filed 2023-03-01 | $65.35M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$36.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$16.53M derived: sum of 2 quarters · filed 2021-11-12 | $6.58M 10-Q · filed 2021-11-12 | $54.08M 10-Q · filed 2020-11-09 | $29.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $19.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $42.92M 10-Q · filed 2021-08-12 | $65.55M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $23.11M 10-Q · filed 2021-05-14 | $45.74M derived: sum of 2 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $22.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $109.73M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $87.10M 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $165.28M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |